What is claimed:

1. Combination vaccine, which comprises i) an avirulent *Lawsonia intracellularis* isolate effective for reducing the incidence of or the lessening the severity of porcine proliferative enteropathy (PPE) caused by *L. intracellularis,* ii) attenuated *Salmonella choleraesuis* effective for the treatment and/or prophylaxis of an infection caused by Salmonella *choleraesuis*, and iii) attenuated *Erysipelothrix rhusiopathiae* effective for the treatment and/or prophylaxis of an infection caused by *Erysipelothrix rhusiopathiae*, and a pharmaceutically acceptable carrier.

2. The combination vaccine according to claim 1, wherein said combination vaccine is to be administered to a non-human animal for the prophylaxis or treatment of diseases and/or lessening of the clinical signs caused by *Salmonelle choleraesuis* and *Erysipelothrix rhusiopathiae*.

3. The combination vaccine according to claim 1 or 2, wherein the avirulent *Lawsonia intracellularis* isolate is modified live *L. intracellularis* isolate.

4. The combination vaccine according to anyone of claims 1 to 3 comprising

i) about 3.0 to about 6.0 $TCID_{50}$ of the modified live *L. intracellularis* per dose and

ii) about $10^{7.0}$ to about $10^{9.0}$ CFU of the attenuated *Salmonella choleraesuis* per dose and

iii) about $10^{8.0}$ to about $10^{10.5}$ CFU of the attenuated *Erysipelothrix rhusiopathiae* per dose.

5. The combination vaccine according to anyone of claims 1 to 3 comprising

i) about 4.0 to about 5.0 $TCID_{50}$ of the modified live *L. intracellularis* per dose and

ii) about $10^{8.0}$ to about $6 \times 10^{8.0}$ CFU of the attenuated *Salmonella choleraesuis* per dose and

iii) about $10^{9.0}$ to about $9 \times 10^{9.0}$ CFU of the attenuated *Erysipelothrix rhusiopathiae* per dose.

6. The combination vaccine according to anyone of claims 1 to 5, wherein i) the avirulent *L. intracellularis* isolate is the bacteria isolate with the ATCC accession No. PTA-4926 or the bacteria isolate with the ATCC accession No. 55783.

7. The combination vaccine according to any one of claims 1 to 6, wherein a single vial mixed formulation of i) and ii) and a single vial formulation of iii), or a single vial mixed formulation of i) and iii) and a single vial formulation of ii) is to be administered.

8. The combination vaccines according to any one of claims 1 to 6 to be administered in form of separate single vial formulations of i), ii) and iii) that are to be administered separately within one week.

9. The combination vaccine according to any one of claims 1 to 6 to be administered in form of a single vial mixture.

10. A kit for the prophylaxis or treatment of diseases and/or lessening of the clinical signs caused by *Salmonella choleraesuis*, and *Erysipelothrix rhusiopathiae* comprising i) avirulent *L. intracellularis* isolate effective for reducing the incidence of or lessening the severity of porcine proliferation enteropathy caused by *L. intracellularis*, and ii) attenuated *Salmonella choleraesuis*, effective in treatment and/or prophylaxis of infections caused by *Salmonella choleraesuis*, and iii) attenuated *Erysipelothrix rhusiopathiae* effective in treatment and/or prophylaxis of infections caused by *Erysipelothrix rhusiopathiae* in one container.

11. A kit for the prophylaxis or treatment of diseases and/or lessening of the clinical signs caused by *Salmonella choleraesuis*, and *Erysipelothrix rhusiopathiae* comprising i) avirulent *L. intracellularis* isolate effective for reducing the incidence of or lessening the severity of porcine proliferation enteropathy caused by *L. intracellularis*, and ii) attenuated *Salmonella choleraesuis*, effective in treatment and/or prophylaxis of infections caused by *Salmonella choleraesuis*, and iii) attenuated *Erysipelothrix rhusiopathiae* effective in treatment and/or prophylaxis of infections caused by *Erysipelothrix rhusiopathiae*;

each in a separate container, or wherein the kit comprises two containers with one container including a mixture of two immunological active components of i)-iii) and one container including the missing immunological component i), ii) or iii).

12. The kit according to claim 10 or 11, wherein the avirulent *Lawsonia intracellularis* isolate is a modified live *L. intracellularis* isolate.

13. The kit according to claim 10 or 11, wherein i) the avirulent *Lawsonia intracellularis* isolate is the bacteria isolate with the ATCC accession No. PTA-4926 or the bacteria isolate with the ATCC accession No. 55783.

14. The kit according to claim 10 or 11, wherein the kit further comprises an instruction letter for the treatment and/or prophylaxis of diseases of swine.

15. Use of the combination vaccine according to anyone of claims 1 to 9 or the kit according to anyone of claims 10 to 14.